Applied Clinical Trials
Telik Reports Progress Toward Multiple Early Stage Milestones in the...
Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers , Aug. 28, 2014 /PRNewswire/ -- Telik, Inc. , a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on , announced today it has made significant progress ... (more)
Telik Receives $1.5 Million National Cancer Institute Contract to...
The contract is intended to support a major portion of the preclinical work being conducted by MabVax, together with its collaboration partner, Memorial Sloan-Kettering Cancer Center to develop a novel Positron Emission Tomography imaging agent for detection and assessment of pancreatic cancer.
Telik, Inc. Announces New Board Of Director Members To Oversee...
Telik, Inc. Announces New Board Of Director Members To Oversee Reinvigorated Cancer Therapy Pipeline Resulting From The Recent Merger With MabVax Therapeutics, Inc. /PRNewswire/ -- Telik, Inc. , a clinical stage oncology drug development company, which recently merged with MabVax Therapeutics, Inc. on , announced the appointment of six new members ... (more)
Telik Announces Plans for Special Meeting of Stockholders and...
As previously announced, MabVax Therapeutics, Inc., a privately held cancer immunotherapy company, and Telik, Inc. , aclinical stage oncology drug development company, completed a merger transaction pursuant to which MabVax became a wholly owned subsidiary of Telik effective as of July 8, 2014, following Telik stockholder approval at Telik's annual ... (more)